Comparison of Subcutaneous Soluble Human Insulin and Insulin Analogues (AspB9, GluB27; AspB10; AspB28) on Meal-Related Plasma Glucose Excursions in Type I Diabetic Subjects

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Diabetes Care

• Publication date

  1991-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/diacare.14.7.571PMID 1914797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Equivalent In Vivo Biological Activity of Insulin Analogues and Human Insulin Despite Different In Vitro Potencies

  1990cited by this paper
• Monomeric Insulins and Their Experimental and Clinical Implications

  1990cited by this paper
• Blood Glucose Area Under the Curve: Methodological Aspects

  1990cited by this paper
• Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes.

  1990cited by this paper
• Glucose control and the renal and retinal complications of insulin-dependent diabetes.

  1989cited by this paper
• Insulin treatment: a decade of change.

  1989cited by this paper
• Modeling absorption kinetics of subcutaneous injected soluble insulin

  1989cited by this paper
• Issues, controversies and directions in diabetes care

  1989cited by this paper
• The pursuit of perfect control in diabetes.

  1988cited by this paper
• Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects.

  1988cited by this paper
• Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo Study.

  1988cited by this paper
• Monomeric insulins obtained by protein engineering and their medical implications

  1988cited by this paper
• Diabetic control and microvascular complications: The near-normoglycaemic experience

  1986cited by this paper
• Effect of insulin antibodies and their kinetic characteristics on plasma free insulin dynamics in patients with diabetes mellitus.

  1986cited by this paper
• Human Insulin

  1986cited by this paper
• Interval between insulin injection and eating in relation to blood glucose control in adult diabetics.

  1985cited by this paper
• Measurement of free insulin concentrations: the influence of the timing of extraction of insulin antibodies

  1985cited by this paper
• Importance of Timing of Preprandial Subcutaneous Insulin Administration in the Management of Diabetes Mellitus

  1983cited by this paper
• Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or bolus injection of the mealtime dose.

  1981cited by this paper
• Normalization of Plasma Insulin Profiles in Diabetic Subjects with Programmed Insulin Delivery

  1980cited by this paper
• “Normal” Insulin Secretion: The Goal of Artificial Insulin Delivery Systems?

  1980cited by this paper
• Timing of pre-breakfast insulin injection and postprandial metabolic control in diabetic children

  1980cited by this paper
• complications of Diabetes Mellitus: Relationship to Metabolic Dysfunction

  1979cited by this paper
• Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance

  1979cited by this paper
• Diabetes Mellitus and Its Degenerative Complications: A Prospective Study of 4,400 Patients Observed Between 1947 and 1973

  1978cited by this paper
• PANCREATIC EXTRACTS

  1977cited by this paper
• Radioimmunological determination of human C-peptide in serum

  1975cited by this paper
• A Simple Method for the Determination of Serum Free Insulin Levels in Insulin-treated Patients

  1973cited by this paper
• Determination of total serum insulin (IRI) in insulin-treated diabetic patients

  1972cited by this paper
• Insulin: The Structure in the Crystal and its Reflection in Chemistry and Biology by

  1972cited by this paper

• Insulin aspart dimer dissociation in water.

  2022cites this paper
• Diabetes Mellitus due to Toxic Misfolding of Proinsulin Variants.

  2021cites this paper
• Structural Lessons From the Mutant Proinsulin Syndrome

  2021cites this paper
• Insulin Centennial: Milestones influencing the development of insulin preparations since 1922

  2021cites this paper
• One-hundred year evolution of prandial insulin preparations: from animal pancreas extracts to rapid-ACTING analogs.

  2021cites this paper
• A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes

  2020cites this paper
• Role of ultrafast-acting insulin analogues in the management of diabetes.

  2019cites this paper
• Premix insulins in type 1 diabetes: the coming of degludec/aspart

  2019cites this paper
• Prospects of intranasal insulin for correction of cognitive impairments, in particular those associated with diabetes mellitus.

  2019cites this paper
• Effect of Ethanol Extract of Moringa Oleifera Leaves in Protecting Anaemia Induced in Rats by Aluminium Chloride

  2018cites this paper
• Evaluation of pharmacokinetic model designs for subcutaneous infusion of insulin aspart

  2017cites this paper
• Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in 1 Humans 2 3

  2016cites this paper
• Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans.

  2016cites this paper
• Cell factories for insulin production

  2014cites this paper
• Current Directions in Insulin-Like Growth Factor Research

  2013cites this paper
• Bioprospecting of Moringa (Moringaceae): Microbiological Perspective

  2013cites this paper
• Insulin Aspart

  2012cites this paper
• A Comparison of Pharmacokinetics and Pharmacodynamics of Insulin Aspart, Biphasic Insulin Aspart 70, Biphasic Insulin Aspart 50, and Human Insulin: A Randomized, Quadruple Crossover Study

  2012cites this paper
• Insulin Aspart

  2012influential citation
• Glycemic variability in type 2 diabetes mellitus: oxidative stress and macrovascular complications.

  2012cites this paper
• Intranasal insulin as a therapeutic option in the treatment of cognitive impairments.

  2011cites this paper
• Insulin X10 revisited: a super-mitogenic insulin analogue

  2011cites this paper
• Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus

  2010cites this paper
• Glucose variability; does it matter?

  2010cites this paper
• Review on the In Vitro Interaction of Insulin Glargine with the Insulin/Insulin-like Growth Factor System: Potential Implications for Metabolic and Mitogenic Activities

  2010cites this paper
• Glycemic variability: too often overlooked in type 2 diabetes?

  2010cites this paper
• A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.

  2009cites this paper
• Design of an Active Ultrastable Single-chain Insulin Analog

  2008cites this paper
• A Subcutaneous Insulin Pharmacokinetic Model for Computer Simulation in a Diabetes Decision Support Role: Validation and Simulation

  2008cites this paper
• A Subcutaneous Insulin Pharmacokinetic Model for Computer Simulation in a Diabetes Decision Support Role: Model Structure and Parameter Identification

  2008cites this paper
• Model-Based Therapeutics for Type 1 Diabetes Mellitus

  2008cites this paper
• Antibody response to insulin in children and adolescents with newly diagnosed Type 1 diabetes

  2008cites this paper
• Intranasal Insulin to Improve Memory Function in Humans

  2007cites this paper
• A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.

  2007cites this paper
• Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart

  2007cites this paper
• Medicamentos análogos de la insulina

  2007cites this paper
• Insulin aspart: a review

  2006influential citation
• Use of new insulins in children

  2006cites this paper
• Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue

  2006influential citation
• Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal‐bolus human insulin treatment in patients with type 1 diabetes

  2006cites this paper
• Therapeutic insulins and their large-scale manufacture

  2005cites this paper
• The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).

  2005cites this paper
• Insulin kinetics in type-1 diabetes: continuous and bolus delivery of rapid acting insulin

  2005cites this paper
• Acute metabolic actions of des-(B27–B30)-insulin and related analogues in adult rats

  2004cites this paper
• Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.

  2003cites this paper
• Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

  2003cites this paper
• Spotlight on Insulin Aspart in Type 1 and 2 Diabetes Mellitus

  2003cites this paper
• Comparison of thrice daily ‘high’ vs. ‘medium’ premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes

  2003cites this paper
• Limitations to subcutaneous insulin administration in type 1 diabetes

  2003cites this paper
• Insulin Regimens for Type 1 Diabetes

  2003cites this paper
• Insulin analogues. A critical review.

  2002cites this paper
• Differences in Pharmacokinetics and Pharmacodynamics of Insulin Lispro and Aspart in Healthy Volunteers

  2002cites this paper
• A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.

  2002cites this paper
• Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.

  2002cites this paper
• Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes.

  2002cites this paper
• Novel insulins: expanding options in diabetes management.

  2002cites this paper
• Insulin aspart: promising early results borne out in clinical practice

  2002cites this paper
• Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients

  2002cites this paper
• Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics.

  2001cites this paper
• Lispro insulin in type 1 diabetic patients on a Mediterranean or normal diet: a randomized, cross-over comparative study with regular insulin.

  2001cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Insulin Aspart

  2001cites this paper
• Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes.

  2001cites this paper
• Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.

  2001cites this paper
• Insulin Aspart: A New Rapid-Acting Insulin Analog

  2000cites this paper
• Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.

  2000cites this paper
• Insulin Aspart

  2000cites this paper
• Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial

  2000cites this paper
• Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers.

  2000cites this paper
• Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in Type 1 diabetes

  2000cites this paper
• Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart

  2000cites this paper
• Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes

  2000cites this paper
• Insulin analogs with improved pharmacokinetic profiles.

  1999cites this paper
• Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes.

  1999cites this paper
• Insulin analogues and their potential in the management of diabetes mellitus

  1999cites this paper
• Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers

  1999cites this paper
• A sedimentation equilibrium study of platypus insulin: the HB10D mutant does not associate beyond dimer.

  1998cites this paper
• Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects

  1998cites this paper
• Comparative pharmacokinetic and pharmacodynamic studies of human insulin and analogues in chronic diabetic Yucatan minipigs.

  1998cites this paper
• Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

  1998cites this paper
• The new era of biotech insulin analogues

  1997cites this paper
• Lispro insulin as premeal therapy in type 1 diabetes: comparison with Humulin R.

  1997cites this paper
• Insulinanaloga und neue Antidiabetika Perspektiven der Diabetestherapie

  1997cites this paper
• Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture

  1997cites this paper
• Insulin formulation and delivery.

  1997cites this paper
• Insulin analogues.

  1997cites this paper
• Reduced Frequency of Severe Hypoglycemia and Coma in Well-Controlled IDDM Patients Treated With Insulin Lispro

  1997cites this paper
• Insulin lispro.

  1997cites this paper
• Insulinanaloga neue Antidiabetika

  1997cites this paper
• Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.

  1997cites this paper
• [Insulin analogs and new antidiabetic agents. Prospects in diabetes therapy].

  1997cites this paper
• Are presently available insulin analogues clinically beneficial?

  1997cites this paper
• Bioavailability and Bioeffectiveness of Subcutaneous Human Insulin and Two of its Analogs—LysB28ProB29-Human Insulin and AspB10LysB28ProB29-Human Insulin—Assessed in a Conscious Pig Model

  1997cites this paper
• Platypus insulin : structural analysis, chemical synthesis and physico-chemical properties

  1996cites this paper
• Prandial Glycaemia After a Carbohydrate‐rich Meal in Type I Diabetic Patients: Using the Rapid Acting Insulin Analogue [Lys(B28), Pro(B29)] Human Insulin

  1996cites this paper
• Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients.

  1996cites this paper
• Advances in the Treatment of Diabetes Mellitus in the Elderly

  1996cites this paper
• Insulin analogs: the virtual reality of normal insulin secretion.

  1995cites this paper
• Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen

  1995cites this paper
• Do Insulin‐treated Diabetic Patients Use an Injection‐meal‐interval in Daily Life?

  1995cites this paper
• Recombinant-DNA-derived insulin analogues as potentially useful therapeutic agents.

  1993cites this paper